Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent ...

* Kroger is working with its merchandising and sourcing teams to diversify the supplier base for some commodities in its ...

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli ...

The investment in the 50,000 sq ft facility by the US-headquartered aeronautical and defense equipment maker is part of its ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

Eli Lilly plans to invest at least $27 billion to build four new manufacturing sites in the U.S., a week after President Trump reportedly said he planned to impose tariffs of 25% or more on ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1. Time and money ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.